Adicet Bio (ACET) vs Cocrystal Pharma (COCP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cocrystal Pharma (COCP) has outperformed Adicet Bio (ACET) over the past year, gaining 5.6% versus a loss of 77.8%. Over five years, COCP leads with a -91.8% price change compared with -98.6% for ACET. Adicet Bio is the larger company by market cap ($20.0 million vs $18.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACET | COCP |
|---|---|---|
| Share price | $2.14 | $0.95 |
| Market cap | $20.03M | $18.30M |
| 1-day change | -13.01% | -2.05% |
| YTD return | -74.58% | -3.06% |
| 1-year return | -77.78% | +5.56% |
| 5-year return | -98.58% | -91.84% |
| EPS (TTM) | $-7.53 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-116.80M | $-8.83M |
| 52-week high | $11.15 | $2.03 |
| 52-week low | $2.12 | $0.76 |
| Distance from 52-week high | -80.81% | -53.20% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1527.57% | +847.37% |
| Average volume | 271.05K | 40.65K |
| Shares outstanding | 9.36M | 19.26M |
| Employees | 102 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COCP has outperformed ACET by 83.3 percentage points over the past year.
About Adicet Bio
ACET stock →Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
About Cocrystal Pharma
COCP stock →Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
ACET vs COCP FAQ
Which is bigger, Adicet Bio or Cocrystal Pharma?
Adicet Bio (ACET) is larger, with a market capitalization of $20.03M compared with $18.30M for Cocrystal Pharma (COCP).
Which stock has performed better over the past year, ACET or COCP?
COCP returned +5.56% over the past 12 months, compared with -77.78% for ACET (price return, excluding dividends). Past performance does not predict future results.
Are Adicet Bio and Cocrystal Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.